Line of credit, related party (Details Narrative) (Mymd Pharmaceuticals Inc.) - Mymd Pharmaceuticals Inc. [Member] - USD ($) |
1 Months Ended | 12 Months Ended | ||
|---|---|---|---|---|
May 31, 2019 |
Dec. 31, 2020 |
Dec. 31, 2019 |
Nov. 10, 2020 |
|
| Unamortized debt discount | $ 1,457,882 | $ 880,020 | ||
| Line of credit | $ 3,192,119 | |||
| Shareholder [Member] | ||||
| Line of credit facility, maximum borrowing capacity | $ 5,000,000 | |||
| Line of credit facility, description | The facility had an initial term of 18 months, which was extended to July 31, 2021 and further extended to December 31, 2022, at which time all outstanding borrowings and accrued interest, if any, are due in full. | |||
| Line of credit facility, interest rate | 5.00% | |||
| Exercise price of common stock option | $ 1.00 | |||
| Lender [Member] | ||||
| Number of common stock options issued | 1,385,241 | 1,920,619 | ||
| Fair market value of common stock options | $ 839,456 | $ 1,165,816 | ||
| X | ||||||||||
- Definition Exercise price of common stock option. No definition available.
|
| X | ||||||||||
- Definition Fair market value of common stock options. No definition available.
|
| X | ||||||||||
- Definition Number of common stock options issued. No definition available.
|
| X | ||||||||||
- Definition Amount, after accumulated amortization, of debt discount. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition The carrying value as of the balance sheet date of the current and noncurrent portions of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition Description of the terms of a credit facility arrangement. Terms typically include interest rate, collateral required, guarantees required, repayment requirements, and restrictions on use of assets and activities of the entity. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition The effective interest rate during the reporting period. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|